Search

Displaying results 4501 - 4510 of 6835 in total
  1. Drug

    Siagoside

    go.drugbank.com/drugs/DB12351
    Investigational

    Sygen appears to be beneficial in patients with severe spinal cord injury. … Treatment results in a 52% decrease in mortality 48 hours after the induction of ischemia in gerbils by permanent unilateral ligation of the common carotid artery.

  2. Drug

    Tanaproget

    go.drugbank.com/drugs/DB04787
    Experimental

    Because of this tanaproget may prove to produce fewer side effects in comparison. It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals. … It is a high affinity, high efficacy agonist of the progesterone receptor (PR) with a much more selective binding profile relative to most conventional progestins.

  3. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    It is being developed by Exelixis, Inc. … Results of single dose Phase I clinical trials of XL784 administered orally to 96 healthy volunteers have demonstrated that XL784 has attractive safety and pharmacokinetic profiles.

  4. Drug

    VIR201

    go.drugbank.com/drugs/DB05110
    Experimental

    The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.

  5. Drug

    Ergosterol

    go.drugbank.com/drugs/DB04038
    ApprovedWithdrawn

    A steroid of interest both because its biosynthesis in FUNGI is a target of ANTIFUNGAL AGENTS, notably AZOLES, and because when it is present in SKIN of animals, ULTRAVIOLET RAYS break a bond to result

  6. Drug

    Topsalysin

    go.drugbank.com/drugs/DB05160
    Investigational

    Topsalysin is delivered locally to the prostate under ultrasound guidance.

  7. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression … Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to

  8. Drug

    Soybean oil

    go.drugbank.com/drugs/DB09422
    ApprovedInvestigational

    Derived from soybeans, soybean oil is a common vegetable oil and a source of polyunsaturated and saturated fatty acids. It is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsatura...

    Mixtures: No name provided
  9. Drug

    Midostaurin

    go.drugbank.com/drugs/DB06595
    ApprovedInvestigational

    It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.

  10. Drug

    Doxapram

    go.drugbank.com/drugs/DB00561
    ApprovedInvestigationalVet approved

    A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)